Galcanezumab Effective at Decreasing Monthly Headache Days in Migraine

Approximately 40% of patients with episodic migraine who were treated with galcanezumab achieved 100% response rate for at least 1 month.

Source link

Related posts

Visual Dysfunction: An Underrecognized Symptom of Parkinson's?


Association of alcohol dehydrogenase and aldehyde dehydrogenase Polymorphism with Spontaneous Deep Intracerebral Haemorrhage in the Taiwan population


New AAN Guidelines for the Management of Disorders of Consciousness


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy